STOCK TITAN

CME Group (CME) director adds shares via market buys and equity awards

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

CME Group Inc. director William R. Shepard increased his stake in the company through a mix of market purchases and stock awards. On June 25, 2026, he made open-market purchases totaling 339.0999 shares of Class A common stock at $230.57 per share, including shares held indirectly through a trust.

On the same date he also acquired 1,067.0000 shares at a reference price of $225.00 per share through fully vested equity awards, shares taken in lieu of cash board retainers, and a dividend reinvestment plan under CME’s non‑employee director programs. Following these transactions, holdings reported include 260,442.3220 shares indirectly by trust and 3,620.7680 shares directly, indicating these moves are small relative to his overall position and largely compensation related.

Positive

  • None.

Negative

  • None.
Insider SHEPARD WILLIAM R
Role null
Bought 339.1 shs ($78K)
Type Security Shares Price Value
Grant/Award Common Stock Class A 645 $225.00 $145K
Grant/Award Common Stock Class A 422 $225.00 $95K
Purchase Common Stock Class A 14.318 $230.57 $3K
Purchase Common Stock Class A 324.782 $230.57 $75K
Holdings After Transaction: Common Stock Class A — 3,184.45 shares (Direct, null); Common Stock Class A — 260,442.322 shares (Indirect, by Trust)
Footnotes (1)
  1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions. At the Reporting Person's election, shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors. The number of shares was determined by dividing the cash retainer by the closing price on the date of grant. Represents shares acquired pursuant to a broker-administered dividend reinvestment plan.
Open-market shares purchased 339.0999 shares Class A common stock bought on June 25, 2026
Open-market purchase price $230.57 per share Price for Class A shares bought June 25, 2026
Equity awards and related shares 1,067.0000 shares Grants, fee-in-shares, and dividend reinvestment at $225.00
Award reference price $225.00 per share Price used to determine director equity awards
Indirect holdings after transaction 260,442.3220 shares Class A shares held indirectly by trust post-transaction
Direct holdings after transaction 3,620.7680 shares Class A shares held directly post-transaction
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
annual equity compensation program financial
"issued as part of the Issuer's annual equity compensation program for non-employee directors"
Director Stock Plan financial
"under the CME Group Director Stock Plan"
dividend reinvestment plan financial
"Represents shares acquired pursuant to a broker-administered dividend reinvestment plan"
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SHEPARD WILLIAM R

(Last)(First)(Middle)
20 S WACKER DRIVE

(Street)
CHICAGO ILLINOIS 60606

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock Class A06/25/2026A(1)645A$2253,184.45D
Common Stock Class A06/25/2026A(2)422A$2253,606.45D
Common Stock Class A06/25/2026P14.318(3)A$230.573,620.768D
Common Stock Class A06/25/2026P324.782(3)A$230.57260,442.322Iby Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.
2. At the Reporting Person's election, shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors. The number of shares was determined by dividing the cash retainer by the closing price on the date of grant.
3. Represents shares acquired pursuant to a broker-administered dividend reinvestment plan.
Remarks:
/s/ Elizabeth Hensen, as Attorney-in-Fact for William R. Shepard06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CME (CME) director William R. Shepard do in this Form 4?

William R. Shepard increased his CME holdings through open-market purchases and stock awards. He bought shares at $230.57 and received fully vested equity grants and dividend reinvestment shares under director compensation programs.

How many CME (CME) shares did William R. Shepard buy on the market?

He purchased 339.0999 shares of CME Class A common stock in open-market transactions. The purchases were executed at a price of $230.57 per share and included both direct holdings and shares held indirectly through a trust.

What stock awards did William R. Shepard receive from CME (CME)?

He acquired 1,067.0000 CME Class A shares via director compensation arrangements. These included fully vested equity grants, shares taken instead of cash retainers, and shares credited through a broker-administered dividend reinvestment plan.

What are William R. Shepard’s CME (CME) holdings after these transactions?

After the transactions, reported holdings include 260,442.3220 CME Class A shares held indirectly by a trust and 3,620.7680 shares held directly. This shows the new transactions are small compared with his total reported position.

Were William R. Shepard’s new CME (CME) shares subject to vesting?

The filing states the grant included fully vested shares of CME Class A common stock. These shares were issued as part of the annual equity compensation program for non-employee directors and are not subject to vesting conditions.

How were some of William R. Shepard’s CME (CME) director fees paid?

At his election, some board cash retainers were taken in CME shares instead of cash. The number of shares was calculated by dividing the retainer amount by CME’s closing stock price on the grant date, according to the disclosure.